IL-23 inhibitor helped patients achieve complete skin clearance and joint symptom improvement
News
Opdivo, Yervoy combination approved to treat malignant pleural mesothelioma
Combination immunotherapy treatment approved in the EU for first-line treatment of adults with unresectable MPM
NICE draft guidance does not recommend Evrysdi for SMA
NICE said it is ‘unable’ to recommend the oral treatment due to high cost-effectiveness estimates
The 2021 Sales Awards welcomes new and returning categories
The Sales Awards have introduced a brand-new category alongside a few returning classics from previous years.
FDA approves Alkermes’ Lybalvi for schizophrenia and bipolar I disorder
Alkermes said that it is expecting to make Lybalvi available for patients in the fourth quarter of 2021
Janssen’s myeloma CAR T therapy cilta-cel demonstrates ‘sustained efficacy’
Updated study results showed an overall response rate of 98% with a longer-term follow-up at a median of 18 months
Cosentyx approved to treat plaque psoriasis in paediatric patients
IL-17A inhibitor has been cleared in the US to treat plaque psoriasis in certain patients aged six years and older
WHO authorises Sinovac’s COVID-19 vaccine for emergency use
A WHO emergency use listing (EUL) is issued when a product meets international standards for safety, efficacy and manufacturing
EC authorises Diurnal’s Efmody for CAH
First commercial launch of Efmody is expected in the third quarter of 2021
University of Bradford to host COVID-19 vaccine booster trial
Trial is being conducted as part of a £90m Department of Health and Social Care (DHSC) initiative
Sanofi halts venglustat clinical programme in ADPKD
Phase II/III trial of the drug did not meet its futility criteria of the annualised rate change in total kidney volume (TKV)
Amgen and Kyowa Kirin agree to jointly develop eczema med
KHK4083 is an anti-OX40, fully human monoclonal antibody in development for the treatment of atopic dermatitis
BREAKING NEWS: UK approves J&J’s one-dose COVID-19 vaccine
UK’s Vaccine Taskforce has secured 20 million doses of the vaccine, with initial deliveries expected ‘later this year’
NICE green lights Tremfya to treat active psoriatic arthritis
Tremfya has already been recommended for NHS use to treat eligible patient with moderate-to-severe plaque psoriasis
Novacyt disputes COVID-19 testing contract with DHSC
Clinical diagnostics company said dispute may have a material impact on its Q1 revenues
